8/7 MannKind - Afrezza Scripts Dip With Quarterly Call On Tap •Afrezza sales dip about 3%. •New RX seems to have a bit more traction. •Refills and cash remain top concerns. https://seekingalpha.com/article/4095774-mannkind-afrezza-scripts-dip#alt1